CJC-1295 research guide for Sunset. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Unlike common nutraceuticals stocked in every health store, CJC-1295 is distributed via a dedicated online market that Sunset residents reach through online vendors. This matters because CJC-1295 quality varies dramatically across the market — from verified research-grade material to mislabeled or underdosed compounds — and the vendor is the entire quality system. Separating properly characterised CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram documenting ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Sunset researchers need to know about purchasing, testing, and working with CJC-1295 for scientific research use.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Sunset comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source CJC-1295 — Vendor Guide
The first step for any Sunset researcher sourcing CJC-1295 is finding vendors with verified community track records — search results alone are too heavily influenced by marketing spend. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are within acceptable research limits. For Sunset researchers evaluating vendors with limited track records: a small initial order to verify quality before placing larger orders is what experienced peptide researchers consistently do. The powdered lyophilised form of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Sunset
COA-verified · International tracking · Research grade
CJC-1295 operates beyond the scope of approved drug regulation — researchers should understand that the known safety profile is based on research literature rather than clinical trials. Temperature excursions — even temporary temperature deviation — can cause partial degradation without visible changes; always use only material shipped with appropriate cold protection. Verify the endotoxin level in your CJC-1295 batch COA before any injectable research application — look for results stated as EU/mg and confirm they fall within appropriate thresholds. Researchers running multi-compound protocols with CJC-1295 should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
